Updated Jul 16, 2026 · Last SEC filing 2026-07-13
Esperion Therapeutics, Inc. (ESPR) has filed 17 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-13. 8 Form 8-K material event filings were reported by ESPR in the last 90 days. 3 Form 144 notices of proposed sale were filed for ESPR stock. InsiderAlpha tracks every ESPR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001434868 |
|---|
| Form 4 filings (90d) | 17 |
|---|---|
| Form 8-K filings (90d) | 8 |
| Form 144 notices (90d) | 3 |
| Latest Form 4 filing | 2026-07-13 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO | D — Derivative transaction | 2.12M | — | — | SEC | |
| CARROLL J MARTIN | Director | D — Derivative transaction | 177.5K | — | — | SEC | |
| Hoffman Robert E. | Director | D — Derivative transaction | 85.2K | — | — | SEC | |
| Harlow John B. Jr. | Chief Commercial Officer | D — Derivative transaction | 424.5K | — | — | SEC | |
| THOMPSON JOHN CRAIG | Director | D — Derivative transaction | 79.9K | — | — | SEC | |
| Shepard Jay | Director | D — Derivative transaction | 164.5K | — | — | SEC | |
| Fischer Seth H. Z. | Director | D — Derivative transaction | 141.0K | — | — | SEC | |
| Halladay Benjamin | Chief Financial Officer | D — Derivative transaction | 705.4K | — | — | SEC | |
| Looker Benjamin | Chief Legal Officer | D — Derivative transaction | 667.5K | — | — | SEC | |
| Halladay Benjamin | Chief Financial Officer | S — Open-market sale | 10.8K | $3.15 | $34K | SEC | |
| Looker Benjamin | Chief Legal Officer | S — Open-market sale | 11.8K | $3.15 | $37K | SEC | |
| Koenig Sheldon L. | President and CEO | S — Open-market sale | 53.6K | $3.15 | $169K | SEC | |
| Fischer Seth H. Z. | Director | A — Grant or award | 79.9K | $0.00 | — | SEC | |
| Hoffman Robert E. | Director | A — Grant or award | 79.9K | $0.00 | — | SEC | |
| Shepard Jay | Director | A — Grant or award | 79.9K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Esperion Therapeutics, Inc. (ESPR). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Koenig Sheldon L. | 5 | $169K |
| Halladay Benjamin | 5 | $34K |
| Looker Benjamin | 5 | $37K |
| Fischer Seth H. Z. | 5 | — |
| Shepard Jay | 5 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ESPR insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ESPR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.